Determination of Tumor Growth Rate in Head and Neck Cancer, Correlation with Possible Prognostic Parameters in the Diagnostic Biopsy

Author(s):  
C.H.J. Terhaard ◽  
L.W. van Bockel ◽  
G.M. Verduyn ◽  
F.A. Pameier ◽  
J.A. Kummer
Molecules ◽  
2019 ◽  
Vol 24 (19) ◽  
pp. 3560
Author(s):  
Li Tian ◽  
Lucas Wang ◽  
Yang Qiao ◽  
Linfeng Lu ◽  
Patrick Lee ◽  
...  

Irreversible electroporation (IRE) kills tumor cells by the delivery of short pulses of strong electric fields. However, the field strength decreases with distance from the treatment center. When IRE cannot eradicate the entire tumor mass, the surviving tumor cells can regrow. NVP-BEZ235 is a dual PI3K/mTOR inhibitor that has been administered orally in clinical trials. However, its hydrophobicity and poor water solubility make NVP-BEZ235 difficult to deliver to target areas. To improve its pharmacokinetics and therapeutic efficacy, we have encapsulated NVP-BEZ235 in a liposome (termed as L-BEZ). Our current study focuses on the long-term antitumor efficacy of IRE and intratumoral injection of L-BEZ in HN5 head and neck cancer xenografts in nude mice. We compared in vitro efficacy, as well as the effect on tumor size and growth rate in vivo, between IRE alone, IRE + oral BEZ, and IRE + L-BEZ over the course of two months. All animals in the control group were sacrificed by day 36, due to excess tumor burden. Tumors treated with IRE alone grew faster and larger than those in the control group. IRE + oral BEZ suppressed tumor growth, but the growth rate increased to that of the controls toward the end of 21 days. Only IRE + L-BEZ eradicated the tumor masses, with no palpable or extractable tumor mass observed after two months. The combination of IRE and L-BEZ could effectively eradicate tumors and prevent recurrence.


2020 ◽  
Vol 25 (7) ◽  
pp. 1270-1277 ◽  
Author(s):  
C. Suzuki ◽  
N. Kiyota ◽  
Y. Imamura ◽  
J. Rikitake ◽  
S. Sai ◽  
...  

2012 ◽  
Vol 18 (20) ◽  
pp. 5639-5649 ◽  
Author(s):  
Yan Zang ◽  
Sufi M. Thomas ◽  
Elena T. Chan ◽  
Christopher J. Kirk ◽  
Maria L. Freilino ◽  
...  

2012 ◽  
Vol 103 ◽  
pp. S59
Author(s):  
H. Stegeman ◽  
J.H.A.M. Kaanders ◽  
A.J. van der Kogel ◽  
M. Iida ◽  
D.L. Wheeler ◽  
...  

2012 ◽  
Vol 18 (10) ◽  
pp. 2850-2860 ◽  
Author(s):  
Sarah E. Wheeler ◽  
Elena M. Morariu ◽  
Joseph S. Bednash ◽  
Charlton G. Otte ◽  
Raja R. Seethala ◽  
...  

2012 ◽  
Vol 05 (04) ◽  
pp. 1250028 ◽  
Author(s):  
YING ZHENG ◽  
QIAOYA LIN ◽  
HONGLIN JIN ◽  
JUAN CHEN ◽  
ZHIHONG ZHANG

The development of experimental animal models for head and neck tumors generally rely on the bioluminescence imaging to achieve the dynamic monitoring of the tumor growth and metastasis due to the complicated anatomical structures. Since the bioluminescence imaging is largely affected by the intracellular luciferase expression level and external D-luciferin concentrations, its imaging accuracy requires further confirmation. Here, a new triple fusion reporter gene, which consists of a herpes simplex virus type 1 thymidine kinase (TK) gene for radioactive imaging, a far-red fluorescent protein (mLumin) gene for fluorescent imaging, and a firefly luciferase gene for bioluminescence imaging, was introduced for in vivo observation of the head and neck tumors through multi-modality imaging. Results show that fluorescence and bioluminescence signals from mLumin and luciferase, respectively, were clearly observed in tumor cells, and TK could activate suicide pathway of the cells in the presence of nucleotide analog-ganciclovir (GCV), demonstrating the effectiveness of individual functions of each gene. Moreover, subcutaneous and metastasis animal models for head and neck tumors using the fusion reporter gene-expressing cell lines were established, allowing multi-modality imaging in vivo. Together, the established tumor models of head and neck cancer based on the newly developed triple fusion reporter gene are ideal for monitoring tumor growth, assessing the drug therapeutic efficacy and verifying the effectiveness of new treatments.


Oral Oncology ◽  
2008 ◽  
Vol 44 (4) ◽  
pp. 383-392 ◽  
Author(s):  
Sun Young Kim ◽  
Yun Soo Yang ◽  
Ki Hwang Hong ◽  
Kyu Yun Jang ◽  
Myoung Ja Chung ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document